(Q46130150)

19 December 2017

title

Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria (English)

1 reference

19 December 2017

cerebral amyloid angiopathy

1 reference

1 reference

Dimitri Renard

1

1 reference

19 December 2017

Giovanni Castelnovo

2

1 reference

19 December 2017

Anne Wacongne

3

1 reference

19 December 2017

Anne Le Floch

4

1 reference

19 December 2017

Eric Thouvenot

5

1 reference

19 December 2017

Julie Mas

6

1 reference

19 December 2017

Audrey Gabelle

7

1 reference

19 December 2017

Pierre Labauge

8

1 reference

19 December 2017

Sylvain Lehmann

9

1 reference

19 December 2017

publication date

11 May 2012

1 reference

19 December 2017

published in

Journal of Neurology

1 reference

19 December 2017

volume

259

1 reference

19 December 2017

issue

11

1 reference

19 December 2017

page(s)

2429-2433

1 reference

19 December 2017

https://scigraph.springernature.com/pub.10.1007/s00415-012-6520-8

exact match

0 references

cites work

Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6520-8

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6520-8

MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6520-8

Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6520-8

Descriptive analysis of the Boston criteria applied to a Dutch-type cerebral amyloid angiopathy population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6520-8

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6520-8

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6520-8

Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6520-8

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6520-8

Plasma β-amyloid levels in cerebral amyloid angiopathy-associated hemorrhagic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6520-8

Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22576334

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Microbleeds relate to altered amyloid-β metabolism in Alzheimer's disease.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22576334

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22576334

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00415-012-6520-8

1 reference

19 December 2017

1 reference

19 December 2017